Y
Y. Wang
Researcher at Janssen Pharmaceutica
Publications - 33
Citations - 5155
Y. Wang is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Ustekinumab & Psoriatic arthritis. The author has an hindex of 16, co-authored 33 publications receiving 4638 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi,Alexa B. Kimball,Kim A. Papp,Newman Yeilding,Cynthia Guzzo,Y. Wang,Shu Li,Lisa T. Dooley,Kenneth B. Gordon +8 more
TL;DR: Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients.
Journal ArticleDOI
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.
Gerald G. Krueger,Richard G. Langley,Craig L. Leonardi,Newman Yeilding,Cynthia Guzzo,Y. Wang,Lisa T. Dooley,Mark Lebwohl +7 more
TL;DR: This double-blind, placebo-controlled trial demonstrates the therapeutic efficacy of an interleukin-12/23 monoclonal antibody in psoriasis and provides further evidence of a role of the interleUKin- 12/23 p40 cytokines in the pathophysiology of Psoriasis.
Journal ArticleDOI
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes,Arthur Kavanaugh,Alice B. Gottlieb,Lluís Puig,Proton Rahman,Christopher T. Ritchlin,Carrie Brodmerkel,Shu Li,Y. Wang,Alan M. Mendelsohn,Mittie K. Doyle +10 more
TL;DR: Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments.
Journal ArticleDOI
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher T. Ritchlin,Proton Rahman,Arthur Kavanaugh,Iain B. McInnes,Lluís Puig,Shu Li,Y. Wang,Yaung-Kaung Shen,Mittie K. Doyle,Alan M. Mendelsohn,Alice B. Gottlieb +10 more
TL;DR: The interleukin-12/23 inhibitor ustekinumab (45/90 mg q12 weeks) yielded significant and sustained improvements in PsA signs/symptoms in a diverse population of patients with active PsA, including anti-TNF-experienced PsA patients.
Journal ArticleDOI
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen,Stacy Smith,Robert Matheson,Craig L. Leonardi,Cesar Calderon,Carrie Brodmerkel,Katherine Li,Kim Campbell,Stanley J. Marciniak,Y. Wasfi,Y. Wang,Philippe Szapary,James G. Krueger +12 more
TL;DR: IL-23 inhibition with a single dose of guselkumab results in clinical responses in patients with moderate-to-severe Psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis.